ReviewDrugs & aging1997
Mammographic screening in older women. Is it worthwhile?
Review in Drugs & aging, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 14 citations in OpenAlex.
- Risk of Breast Cancer Revealed by Mammographic Screening in Czech Women Aged 40-45 Years, a Monocentric Cohort Study.Diagnostics (Basel, Switzerland) · 2020Article
- Screen-detected breast cancers have a lower mitotic activity index.British journal of cancer · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal upper age limit in mammographic screening for breast cancer is still a matter for debate. The incidence of breast cancer rises gradually with increasing age and, without screening, breast cancer in elderly women is diagnosed at a more advanced stage than in younger women. After menopause, much of the glandular tissue of the breast is replaced by fat, which facilitates the mammographic detection of breast cancer in older women. Furthermore, the tumour growth rate decreases with increasing age. Recently, a reduction in breast cancer mortality due to mammographic screening has been shown for women aged up to 75 years. There is a lack of data for women over the age of 75 years, however, because the number of women screened in the only study that included this age category is too small to give reliable results. We conclude that mammographic screening is beneficial at least up to the age of 75 years, and may also be beneficial up to age 85 years in healthy women with a good life expectancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.